Home Biosimilar Antibodies Cytoskeletal Signaling Tight Junction Protein Zolbetuximab (Anti-CLDN18.2)
For research use only. Not for use in humans.

Zolbetuximab (Anti-CLDN18.2)

Synonyms: SFTA5,SFTPJ

Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD.

Zolbetuximab (Anti-CLDN18.2)

Quality Control

Batch: Purity: 99% Protein concentration: 5.416mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD.
References

Product Details

CAS No. 1496553-00-4
Molecular Weight 150
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06962137 RECRUITING Drug: zolbetuximab Gastric Cancer Adenocarcinoma Metastatic; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma Universitaire Ziekenhuizen KU Leuven 2025-12-11 PHASE2
NCT07431281 RECRUITING Drug: Sonesitatug vedotin|Drug: Rilvegostomig|Drug: Nivoluma Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer AstraZeneca 2026-02-03 PHASE3
NCT06881017 NOT_YET_RECRUITING Drug: Trastuzumab|Drug: Adebrelimab|Drug: Apatinib|Drug: S-1 Gastric Cancer; HER2 + Gastric Cancer; CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction; PD-L1 Positive China Medical University, China 2025-05-01 PHASE2
NCT07723534 NOT_YET_RECRUITING Drug: Zolbetuximab|Drug: mFOLFOX6|Drug: CAPOX Advanced Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma Midhun Malla 2026-08 PHASE2
NCT07290985 RECRUITING Drug: Tislelizumab|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Gastroesophageal Adenocarcinoma American Association for Cancer Research 2026-07-20 PHASE2
NCT06732856 RECRUITING Drug: zolbetuximab|Drug: Oxaliplatin|Drug: Docetaxel|Drug: S Stomach Neoplasm; Gastric (Stomach) Cancer Asan Medical Center 2025-04-04 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-12-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.